Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients and pharmaceutical intermediates, cooperative R & D, custom manufacturing, sales and service as well as import of pharmaceutical raw materials.
Our company's various chemical qualifications and certificates are complete, there are a variety of pharmaceutical intermediates and precursor chemicals, and most of the common dangerous goods business qualifications, and have complete import and export qualifications, the company's products are sold all over the world, and Acting for the import and export of various products such as hazardous chemicals.
The company is mainly engaged in wholesale, retail, biological products, pharmaceutical intermediates, first-class medical equipment, petroleum products, rubber products, plastic products, biological reagents, biochemical testing reagents and consumables, chemical reagents; pharmaceutical operations (operating with valid licenses) Import and export of goods and technology (except for projects prohibited by national laws and administrative regulations, and laws and administrative regulations stipulate that projects that restrict operations can only be operated after obtaining a permit). (Projects subject to approval according to law may be operated after approval by relevant departments).We, Jeci Biochem, can supply intermediates related to antihypertensive drugs. Inquiries are welcome!
Recently, AstraZeneca announced that the marketing application for its investigational therapy Baxdrostat has been accepted by the U.S. FDA and granted Priority Review status. It is intended as an add-on treatment to other antihypertensive agents for adult patients with resistant hypertension (uncontrolled or treatment-resistant) whose blood pressure cannot be adequately lowered by existing medications. The FDA expects to complete its review in the second quarter of 2026. If approved, Baxdrostat will become the world's first marketed aldosterone synthase inhibitor (ASI), marking a breakthrough in hypertension treatment.
Baxdrostat is a highly selective, potent oral small-molecule aldosterone synthase inhibitor acquired by AstraZeneca through its acquisition of CinCor Pharma. It directly lowers aldosterone levels by specifically inhibiting the last three rate-limiting steps of aldosterone synthesis in the adrenal glands. Unlike traditional antihypertensives such as beta-blockers or ARBs, Baxdrostat's innovation lies in precisely targeting the aldosterone synthesis pathway, with >100-fold selectivity over cortisol synthesis enzymes, thereby avoiding side effects associated with cortisol dysregulation. This mechanism is particularly suited for patients whose blood pressure remains uncontrolled after treatment with multiple existing drugs, offering them a new solution.
The marketing application for Baxdrostat is based on results from the Phase III BaxHTN study. The trial enrolled 796 patients with resistant hypertension and showed:
At 12 weeks, the 2 mg dose group achieved a mean reduction in seated systolic blood pressure (SBP) of 15.7 mmHg, the 1 mg group 14.5 mmHg, compared with only 5.8 mmHg in the placebo group. After placebo correction, the 2 mg and 1 mg groups achieved significant reductions of 9.8 mmHg and 8.7 mmHg, respectively (p < 0.001).
In 24‑hour ambulatory BP monitoring, the Baxdrostat 2 mg group reduced nighttime SBP by 13.9 mmHg (p < 0.0001), effectively covering the high-risk early morning period for cardiovascular events.
The rate of BP control (SBP < 130 mmHg) increased nearly threefold, with 71% of patients achieving sustained 24‑hour BP control.
In terms of safety, Baxdrostat was well tolerated, with no unexpected adverse events; most adverse reactions were mild. These data were presented at the 2025 European Society of Cardiology (ESC) Congress and simultaneously published in The New England Journal of Medicine.
The market potential for antihypertensive drugs is enormous. According to PharmCube data, sales of antihypertensive chemical drugs across China's three major terminals exceeded RMB 78.9 billion in 2024. Globally, there are 1.4 billion people with hypertension, about 25% of whom have aldosterone dysregulation, while resistant hypertension accounts for 30%–50%, representing a vast unmet clinical need.
Currently, competition in the ASI field is heating up. In addition to Baxdrostat, Mineralys' Lorundrostat and Boehringer Ingelheim's BI 690517 are both in Phase III development, and domestic companies such as Salubris and Hansoh Pharma have also entered the space. With its Priority Review designation and earlier filing timeline, Baxdrostat is poised to reach the market first and seize a competitive advantage.
For AstraZeneca, Baxdrostat is not only a breakthrough in hypertension but also a key growth driver for its Cardiovascular, Renal and Metabolism (CVRM) franchise. As its blockbuster product dapagliflozin approaches patent expiry, Baxdrostat could synergize with GLP‑1 drug AZD5004, lipid-lowering agent AZD0780, and others to build a "heart–kidney–metabolism" therapeutic matrix. In the future, if its indications expand to heart failure and chronic kidney disease, it will further consolidate AstraZeneca's leadership in CVRM and support its goal of $80 billion in revenue by 2030.
